Finoriq research workspace
Kiniksa Pharmaceuticals International, plc (KNSA) Company Overview
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes. Review KNSA filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
- Company
- Kiniksa Pharmaceuticals International, plc (KNSA)
- Ticker
- KNSA
- Market Cap
- $4.8B
- Latest Price
- $62.69
- Industry
- Biotech & Pharma
Kiniksa Pharmaceuticals International, plc (KNSA) Current Valuation Metrics
Static valuation preview for Kiniksa Pharmaceuticals International, plc (KNSA). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/EMarket cap divided by latest TTM net income. | 67.8x | Net Income | TTM Q1 2026 |
| P/SMarket cap divided by latest TTM revenue. | 6.57x | Revenue | TTM Q1 2026 |
| P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow. | 29.9x | Operating Cash Flow | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | 1.5% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | 3.3% | Operating Cash Flow | TTM Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.